Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ocular hypertension or primary open-angle glaucoma in each eye~* Requires treatment with IOP-lowering medication in both eyes~Exclusion Criteria:~* Required chronic use of ocular medications during the study other than study medication~* Use of any corticosteroids within 30 days~* History of any prior eye surgery, except for uncomplicated eye surgery performed more than 6 months before the Screening visit~* Anticipated wearing of contact lenses during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triple Combination Therapy (Type: EXPERIMENTAL): Triple Combination Therapy with bimatoprost/brimonidine tartrate/timolol ophthalmic solution. One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
- Combigan® (Type: ACTIVE_COMPARATOR): Fixed Combination brimonidine tartrate/timolol ophthalmic solution (Combigan®). One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).